Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lee Choo-Kang

Pediatric Pulmonology Saint Louis, MO Medical Doctor

NPI 1144366196 CMS profile 97536

621 S New Ballas Rd, Suite 382-A, Saint Louis, MO 63141

Open in the dashboard

General payments

$9,540

202 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lee Choo-Kang of Saint Louis, MO is reported in the CMS Open Payments database as having received $9,540 across 202 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Pediatric Pulmonology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $240 7
2024 General $563 26
2023 General $552 26
2022 General $571 24
2021 General $2,237 37
2020 General $387 23
2019 General $4,989 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lee Choo-Kang
  • Pediatric Pulmonology median
  • Middle half of Pediatric Pulmonology
  • National median

In program year 2025, general payments to Lee Choo-Kang were reported at $240. Among 622 Pediatric Pulmonology profiles paid that year, the median was $139 and the middle half received between $60 and $405.

Show as a table
Year Lee Choo-Kang Pediatric Pulmonology median Middle half National median
2019 $4,989 $151 $59–$495 $163
2020 $387 $107 $34–$339 $114
2021 $2,237 $125 $40–$511 $132
2022 $571 $133 $49–$428 $149
2023 $552 $138 $44–$494 $160
2024 $563 $132 $46–$398 $164
2025 $240 $139 $60–$405 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech USA, Inc. $5,669 20 payments
  2. AstraZeneca Pharmaceuticals LP $1,074 49 payments
  3. GlaxoSmithKline, LLC. $565 31 payments
  4. Regeneron Healthcare Solutions, Inc. $555 21 payments
  5. Jazz Pharmaceuticals Inc. $313 9 payments
  6. AbbVie, Inc. $258 15 payments
  7. Genzyme Corporation $225 12 payments
  8. Philips Electronics North America Corporation $196 9 payments
  9. kaleo, Inc. $131 8 payments
  10. Chiesi USA, Inc. $120 4 payments
  11. Other $434 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $4,590 2 payments
  2. Food and Beverage $4,291 193 payments
  3. Travel and Lodging $557 4 payments
  4. Gift $76 1 payment
  5. Education $25 2 payments
Products named General payments · program years 2019–2025
  1. Xolair $5,565 19 payments
  2. DUPIXENT Inflammation And Immunology $555 21 payments
  3. FASENRA $452 20 payments
  4. NUCALA Immunology $377 19 payments
  5. CREON $246 14 payments
  6. TEZSPIRE $236 11 payments
  7. DUPIXENT Immunology $218 11 payments
  8. SYMBICORT $196 13 payments
  9. NUCALA Respiratory $188 12 payments
  10. XYREM $158 6 payments
  11. Other $1,207 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Pulmonology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record